Hep C Discussion Forum

Members Login
Username 
 
Password 
    Remember Me  
Chatbox
Please log in to join the chat!
Hep C Discussion Forum -> Hep C News -> FDA Approves Daklinza (daclatasvir) for the Treatment of Patients with Gen. 3
Post Info TOPIC: FDA Approves Daklinza (daclatasvir) for the Treatment of Patients with Gen. 3
Tig


Admin

Status: Offline
Posts: 9270
Date:
RE: FDA Approves Daklinza (daclatasvir) for the Treatment of Patients with Gen. 3
Permalink  
 

Hey Nirmalee,

I love your upbeat message! We need to hear these kinds of positive and informative posts. It really makes an important statement for those coming behind us. I'm thrilled to hear you're improving so well! Keep it up smile



__________________

Tig

67yo GT1A - 5 Mil - A2/F3 - (1996) Intron A - Non Responder, (2013) Peg/Riba/Vic SOT:05/23/13 EOT:12/04/13 SVR 9+ years!

Hep C FAQ   Lab Ref. Ranges  HCV Resistance

Signature Line Set Up/Abbreviations   Payment Assistance

 
dragonfly


Senior Member

Status: Offline
Posts: 395
Date:
Permalink  
 

This is the best chance for geno 3s.  I had failed 2 lots of other treatment and on this I was clear within 2 weeks!  I am so happy that this opportunity is available to others now.  If you get offered it - take it and it will change your life.  I have lived with increasingly debilitating symptomns for a very long time and now they are gone.  I no longer have that awful pressure in my ribcage or referred pain in my shoulder.  My illness no longer dictates my life.

Best wishes,

Nirmalee



__________________
Groupergetter


Guru

Status: Offline
Posts: 796
Date:
Permalink  
 

Jill, I had overlooked this newly approved treatment for the US market.  Folks with genotype 3 may find it interesting.   Thanks for sharing



__________________

1b  Int/Riba relapse @ 48 weeks.  Stop tx Peg Int/Riba 12 weeks ill. Relapse S/O 6/23/14 :(   Started Harvoni 11/12/14  EOT 4/28/15.  EOT+4 UND :)  SVR! 8/4/15  :)     Thankful for every morning.
Cinnamon Girl


Guru

Status: Offline
Posts: 5629
Date:
Permalink  
 

Bristol-Myers Squibb Company announced today (24 July, 2015) that Daklinza (daclatasvir), an NS5A replication complex inhibitor, has been approved by the U.S. Food and Drug Administration (FDA). 

This approval marks the first time patients with chronic hepatitis C virus (HCV) genotype 3 have a 12-week, once-daily, all-oral treatment option.  Daklinza is indicated for use with sofosbuvir for the treatment of patients with chronic HCV genotype 3 infection.

Sustained virologic response (SVR) rates are reduced in HCV genotype 3-infected patients with cirrhosis receiving this regimen.  The recommended dosage of Daklinza is 60 mg in combination with sofosbuvir for 12 weeks.

Link to full details of press release...

 

http://www.businesswire.com/news/home/20150724005696/en/FDA-Approves-Daklinza-daclatasvir-Treatment-Patients-Chronic#.VbeoR7Zkih9



__________________

Jill 

(71 yo, lives in UK)

Was Gen 3a, 

24wks Peg Ifn/Riba, Sep 2010 - Mch 2011

UND @ Wk.4, UND @ EOT, 

SVR Nov 2011 --> Still UND @ EOT + 4 yrs.

 

 
Page 1 of 1  sorted by
 
Quick Reply

Please log in to post quick replies.
Hep C Discussion Forum -> Hep C News -> FDA Approves Daklinza (daclatasvir) for the Treatment of Patients with Gen. 3
Legal Disclaimer:

THIS FORUM, IT'S OWNERS, ADMINISTRATORS, MODERATORS AND MEMBERS DO NOT AT ANY TIME GIVE MEDICAL ADVICE AND IN ALL CASES REFER ANYONE HERE TO SEEK APPROPRIATE MEDICAL ADVICE FROM THEIR DOCTOR.